SMOK-study: SSRI Medication in pregnant women: Effect on development of children.

SMOK-study: SSRI Medication in pregnant women: Effect on development of children

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22808

Enrollment

120

Registered

2006-10-18

Start date

2007-04-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The use of SSRI by pregnant women.

Interventions

SSRI

Eligibility

Inclusion criteria

Inclusion criteria: Newborn child exposed to an SSRI in utero.

Exclusion criteria

Exclusion criteria: Newborn child exposed to a non-SSRI antidepressant in utero. Newborn child exposed to anti-epileptic drugs in utero.

Design outcomes

Primary

Measure	Time frame
In the first week after birth and at 3 months post-term: Quality of general movements. At the age of 2 years and 6 years: Motor and cognitive development.	—

Contacts

Public ContactC.N. Veere, van der

University Medical Center Groningen (UMCG), Beatrix Children's Hospital, P.O. Box 30001

c.n.van.der.veere@bkk.umcg.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)